netFormulary NHS
Isle of Wight
Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Chemotherapy drugs are frequently given in combination.

Disease specific protocols are approved at local and network level.

Only approved protocols should be used. All chemotherapy treatment decisions should be made by a consultant grade oncologist or haematologist, with input from the relevant multidisciplinary team. 

 Chemotherapy drugs, including oral therapies must be prescribed, dispensed and administered only by suitably trained staff. 

Paediatric cancer therapies are initiated and prescribed from tertiary cancer centres. The exception is maintenance treatment for some cancers, which is prescribed by designated paediatricians only.

Cancer Drugs Fund (CDF) - Drug List

Chapter Links...
 Details...
08.01.03  Expand sub section  Antimetabolites
Cytotoxic Drug Azacitidine (Vidaza®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA218: azacitidine for myelodysplastic syndromes
Link  NICE TA399: Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blasts
Cytotoxic Drug Capecitabine (Xeloda®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA100: Colon cancer (adjuvant) - capecitabine and oxaliplatin
Link  NICE TA191: Gastric cancer (advanced) - capecitabine
Link  NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Cytotoxic Drug Cytarabine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Fludarabine Phosphate
(Fludara®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA119: Leukaemia (lymphocytic) - fludarabine
Cytotoxic Drug Fluorouracil
(Chemotherapy)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Gemcitabine (Gemzar®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA116: Breast cancer - gemcitabine
Link  NICE TA389 - Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Cytotoxic Drug Mercaptopurine
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Methotrexate
(Chemotherapy)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Cytotoxic Drug Pemetrexed (Alimta®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA135: Mesothelioma - pemetrexed disodium
Link  NICE TA181: Lung cancer (non-small cell, first line treatment) - pemetrexed
Link  NICE TA190: Lung cancer (non-small-cell) - pemetrexed (maintenance)
Link  NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Cytotoxic Drug Raltitrexed (Tomudex®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Drugs that may be initiated, stabilised and maintained by primary, secondary or tertiary care Secondary and tertiary care prescribing may be continued by primary care. [this does not indicate first/second line choice]  

Green Hospital

Items used by the Hospital but would not normally be continued into primary care. Primary care prescribers can change to GREEN first or second.   

Green plus

Initiation of drugs by primary care following written advice from secondary/ tertiary care advice.  

Yellow

Drugs that may be continued in primary care following initiation and stabilisation in secondary/tertiary care  

Amber

Items requiring a shared care agreement. These items should be initiated and stabilised by secondary or tertiary care. The GP should only be asked to take over prescribing through a formal shared care agreement. Secondary care will be expected to continue prescribing until the agreement is made.  

Red

Hospital/ Trust ONLY. These are items the secondary and tertiary care are responsible for prescribing and will need to continue to prescribe for long term maintenance. These items will NOT be prescribed in primary care. But primary care should be informed the patient is receiving these items. This will include NHSE funded items requiring repatriation.  

GP - Black

Items covered by NHSE ‘Should not prescribe in primary care list’ – See CCG policy on Drugs of limited clinical value  

GP - Grey

Grey List: Items covered by NHSE ‘Should not prescribe in primary care list’ that are not to be routinely prescribed but may be suitable in a defined population – See CCG policy on Drugs of limited clinical value  

netFormulary